Tabaei Samira, Haghshenas Mohammad Reza, Ariafar Ali, Gilany Kambiz, Stensballe Allan, Farjadian Shirin, Ghaderi Abbas
Department of Immunology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Clin Proteomics. 2023 Jul 27;20(1):28. doi: 10.1186/s12014-023-09419-8.
Non-muscle-invasive bladder cancer (NMIBC) has a high recurrence rate and muscle-invasive bladder cancer (MIBC) has unfavorable outcomes in urothelial bladder cancer (UBC) patients. Complex UBC-related protein biomarkers for outcome prediction may provide a more efficient management approach with an improved clinical outcome. The aim of this study is to recognize tumor-associated proteins, which are differentially expressed in different stages of UBC patients compared non-cancerous tissues.
The proteome of tissue samples of 42 UBC patients (NMIBC n = 25 and MIBC n = 17) was subjected to two-dimensional electrophoresis (2-DE) combined with Liquid chromatography-mass spectrometry (LC-MS) system to identify differentially expressed proteins. The intensity of protein spots was quantified and compared with Prodigy SameSpots software. Functional, pathway, and interaction analyses of identified proteins were performed using geneontology (GO), PANTHER, Reactome, Gene MANIA, and STRING databases.
Twelve proteins identified by LC-MS showed differential expression (over 1.5-fold, p < 0.05) by LC-MS, including 9 up-regulated in NMIBC and 3 up-regulated in MIBC patients. Proteins involved in the detoxification of reactive oxygen species and cellular responses to oxidative stress showed the most significant changes in UBC patients. Additionally, the most potential functions related to these detected proteins were associated with peroxidase, oxidoreductase, and antioxidant activity.
We identified several alterations in protein expression involved in canonical pathways which were correlated with the clinical outcomes suggested might be useful as promising biomarkers for early detection, monitoring, and prognosis of UBC.
在尿路上皮膀胱癌(UBC)患者中,非肌层浸润性膀胱癌(NMIBC)复发率高,而肌层浸润性膀胱癌(MIBC)预后不佳。用于预后预测的复杂UBC相关蛋白质生物标志物可能提供一种更有效的管理方法,改善临床结果。本研究的目的是识别与肿瘤相关的蛋白质,这些蛋白质在UBC患者的不同阶段与非癌组织相比存在差异表达。
对42例UBC患者(NMIBC患者25例,MIBC患者17例)的组织样本蛋白质组进行二维电泳(2-DE)结合液相色谱-质谱(LC-MS)系统分析,以鉴定差异表达的蛋白质。使用Prodigy SameSpots软件对蛋白质斑点的强度进行定量和比较。利用基因本体论(GO)、PANTHER、Reactome、Gene MANIA和STRING数据库对鉴定出的蛋白质进行功能、通路和相互作用分析。
LC-MS鉴定出的12种蛋白质显示出差异表达(超过1.5倍,p<0.05),其中9种在NMIBC患者中上调,3种在MIBC患者中上调。参与活性氧解毒和细胞对氧化应激反应的蛋白质在UBC患者中变化最为显著。此外,与这些检测到的蛋白质最相关的潜在功能与过氧化物酶、氧化还原酶和抗氧化活性有关。
我们确定了几种参与经典通路的蛋白质表达改变,这些改变与临床结果相关,可能有望作为UBC早期检测、监测和预后的生物标志物。